Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Global Peanut Allergy Treatment Research Report 2023-2028: Pioneering Treatments Across Antihistamines, Epinephrine, & Immunotherapies Emerge Amid Rising Peanut Allergy Cases

Research and Markets Logo

News provided by

Research and Markets

Aug 25, 2023, 13:30 ET

Share this article

Share toX

Share this article

Share toX

DUBLIN, Aug. 25, 2023 /PRNewswire/ -- The "Peanut Allergy Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (Antihistamines, Epinephrine, Immunotherapies, Others), By Route of Administration, By Distribution Channel, By Region and Competition" report has been added to  ResearchAndMarkets.com's offering.

Global Peanut Allergy Treatment Market readies itself for a remarkable surge in growth during the projected period spanning from 2024 to 2028

This surge is rooted in the escalating awareness surrounding peanut allergies and the striking advancements in technology that have taken place. Peanut allergy, a potentially life-threatening condition that casts its shadow across millions globally, has thrust the Peanut Allergy Treatment Market into a rapid expansion in recent times, driven by the growing prevalence of this allergic affliction and the compelling need for efficacious remedies.

The crux of this growth narrative lies in the strides made within research, unraveling the intricate mechanics of peanut allergies, thus engendering the emergence of treatments that are targeted and more potent. Notably, pioneering achievements such as allergen-specific immunotherapy and gene therapies have flourished on the back of biotechnological breakthroughs and genetic engineering marvels.

Furthermore, the regulatory landscape has proven instrumental, with esteemed agencies like the FDA and the European Medicines Agency (EMA) penning guidelines to elevate the safety and efficacy benchmarks of peanut allergy treatments. The stage has witnessed a flurry of product launches in recent years, expanding the horizons of treatment possibilities and kindling a ray of hope for those navigating the challenges posed by peanut allergies.

Within this intricate tapestry, trends such as immunotherapy, epinephrine auto-injectors, refined food labeling, innovative dietary alternatives, and the remarkable potential of gene therapy intertwine to shape the landscape of peanut allergy treatment. Chief among these is immunotherapy, a resounding paradigm that diminishes the severity of peanut-triggered allergic reactions.

However, this promising narrative is not without its challenges, as the growth of the Global Peanut Allergy Treatment Market contends with hurdles ranging from the specter of severe allergic reactions to impediments in accessibility, soaring costs, limited effectiveness, and a broader lack of comprehension surrounding the ailment.

Increasing Awareness of Peanut Allergy

The increasing prevalence of peanut allergy is driving the growth of the Global Peanut Allergy Treatment Market. Peanut allergies have become a significant public health concern, affecting millions of people worldwide, and the number of cases continues to rise.

As a result, there is an increasing demand for effective treatments for peanut allergies. This has led to the development of various products and therapies that can help manage and treat peanut allergies, such as peanut allergy immunotherapy, oral immunotherapy, and sublingual immunotherapy.

The market is being driven by increased investments in research and development activities by pharmaceutical companies and government organizations to develop effective treatments for peanut allergies. Additionally, the increasing awareness about peanut allergies among the general population is expected to boost the demand for peanut allergy treatments in the coming years.

Growing Awareness Regarding the Peanut Allergy

The growing understanding of peanut allergy is influencing the growth of the Global Peanut Allergy Treatment Market. With advances in medical research, there is a greater understanding of the causes and mechanisms of peanut allergy, which is leading to the development of new and more effective treatments.

For example, researchers are now exploring new approaches to immunotherapy that could provide longer-lasting protection against peanut allergies. Additionally, new diagnostic tools are being developed that can help physicians more accurately diagnose and manage peanut allergies.

As the understanding of peanut allergies continues to grow, it is likely to fuel demand for new and innovative treatments. This is particularly true as more people become aware of the serious health risks associated with peanut allergies and the impact they can have on quality of life.

Furthermore, the increasing awareness of peanut allergies has led to more funding being directed towards research and development of new treatments for peanut allergies. This, in turn, is driving the growth of the Global Peanut Allergy Treatment Market as companies are developing new products and therapies to meet the needs of patients.

The growing understanding of peanut allergies has a significant impact on the growth of the Global Peanut Allergy Treatment Market.

Increasing Investment in Research & Development

Increasing investment in research and development is a major driver of the growth of the Global Peanut Allergy Treatment Market. As the prevalence of peanut allergy continues to rise, there is a growing need for more effective treatments, which has led to increased investment in research and development activities.

Pharmaceutical companies, government organizations, and research institutions are investing heavily in developing new and innovative treatments for peanut allergy. For example, there is ongoing research into new types of immunotherapies, including oral and sublingual immunotherapy, as well as the development of new peanut allergy vaccines.

These investments are also driving the development of more accurate and efficient diagnostic tools for peanut allergies, which will help physicians to diagnose and manage the condition more effectively.

Moreover, the increasing investment in research and development activities has led to the discovery of new and innovative methods for peanut allergy treatment. This includes novel formulations of existing drugs, as well as new delivery mechanisms for these drugs.

Competitive landscape

Company Profiles: Detailed analysis of the major companies present in Global Peanut Allergy Treatment Market.

  • Vedanta Biosciences, Inc.
  • Alladapt Immunotherapeutics, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Aravax Pty Ltd
  • Teva Pharmaceutical Industries Limited
  • Prota Therapeutics Pty Ltd.
  • Aimmune Therapeutics, Inc. (Nestle)
  • DBV Technologies SA
  • Sanofi SA

Report Scope:

Global Peanut Allergy Treatment Market, By Drug Class:

  • Antihistamines
  • Epinephrine
  • Immunotherapies
  • Others

Global Peanut Allergy Treatment Market, By Route of Administration:

  • Oral
  • Intravenous
  • Others

Global Peanut Allergy Treatment Market, By Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

For more information about this report visit https://www.researchandmarkets.com/r/3zcwup

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.